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The biology and pathogenesis of hepatitis E virus are poorly
understood due to the lack of an in vitro culture or infection
models. The viral Orf3 protein activates the cellular mitogen-
activated protein kinase pathway and is likely to modulate the
host cell environment for efficient viral replication. We
screened for cellular genes whose transcription was differen-
tially up-regulated in anOrf3-expressing stable cell line (ORF3/
4). The gene for mitochondrial voltage-dependent anion chan-
nel (VDAC) was one such candidate. The up-regulation of
VDAC inORF3/4 cells was confirmed byNorthern andWestern
blotting in various cell lines. Transfection of ORF3/4 cells with
an ORF3-specific small interfering RNA led to a reduction in
VDAC protein levels. VDAC is a critical mitochondrial outer
membrane protein, and its overexpression results in apoptosis.
Surprisingly, Orf3-expressing cells were protected against stau-
rosporine-induced cell death by preservation of mitochondrial
potential andmembrane integrity.A small interferingRNA-me-
diated reduction in Orf3 and VDAC levels also made cells sen-
sitive to staurosporine. Chemical cross-linking showed Orf3-
expressing cells to contain higher levels of oligomeric VDAC.
These cells also contained higher levels of hexokinase I that
directly interacted with VDAC. This interaction is known to
preserve mitochondrial potential and prevent cytochrome c
release. We report here the first instance of a viral protein pro-
moting cell survival through such a mechanism.
Hepatitis E virus (HEV)4 is the causative agent of hepatitis E,
a major form of viral hepatitis in developing countries (1–3). It
is a waterborne pathogen that is transmitted primarily through
the feco-oral route, causing rampant sporadic infections and
large outbreaks in endemic areas (1–3). Although the infection
is self-limited and never proceeds to chronicity, fulminant hep-
atitis with high rates of mortality is known to occur in a small
fraction of patients, especially in pregnant women (4, 5). The
HEVwas recently classified as the onlymember ofHepevirus in
the family Hepeviradae (6). It is a nonenveloped virus with a
single-stranded positive sense RNA genome of 7.2 kb and
contains three open reading frames (ORFs) (7). The orf1
encodes themajor nonstructural polyprotein, orf2 codes for the
major viral capsid protein, and orf3 codes for a small protein
whose functions are not fully understood. Due to the lack of
reliable cell culture systems or small animalmodels of infection
and disease, subgenomic expression strategies have been
employed to functionally characterize HEV-encoded proteins
(8–10).
The orf3 overlaps the other two ORFs and encodes a protein
of 123 amino acids (Orf3). A recent report proposes that Orf2
and Orf3 are translated from the same subgenomic RNA and
that the latter protein was 9 amino acids shorter at its N-termi-
nal end than previously reported (11). TheOrf3 protein is phos-
phorylated at a single serine residue by the cellular mitogen-
activated protein kinase (9). In its N-terminal half, Orf3
contains two hydrophobic domains, the first shown to be
responsible for its cytoskeletal association (9). In its C-terminal
half, the protein contains two proline-rich regions, of which
one carries the phosphorylated serine residue (9). The other
region was shown to contain a PXXPXXP motif and to bind
several proteins that contain Src homology 3 domains (12).
Such PXXP motifs are part of polyproline helices found in a
number of viral and cellular proteins involved in signal trans-
duction and bind the Src homology 3 domains found in a
diverse group of signal-transducing molecules (13, 14). Previ-
ously, we have also shown Orf3 to activate the extracellularly
regulated kinase (ERK), a member of the mitogen-activated
protein kinase superfamily, supporting a prosurvival role for it.
The Orf3 protein binds Pyst1, an ERK-specific member of dual
specificitymitogen–activated protein kinase phosphatases; this
interaction inhibits ERK dephosphorylation, thereby prolong-
ing its activated state (15).
In the present study, we found increased expression of the
voltage-dependent anion channel (VDAC) protein in Orf3-ex-
pressing cells. The VDAC protein, also known as porin for its
pore forming ability, is a resident outer mitochondrial mem-
brane (OMM) protein of 30–35 kDa that regulates the trans-
port of solutes such as Ca2 andATP across theOMM (16, 17).
The mitochondrion plays an important and fateful role in the
apoptotic death of mammalian cells by releasing apoptogenic
proteins into the cytoplasm (18). The release of cytochrome c
from mitochondria into the cytoplasm activates caspases, set-
ting the cell on an apoptotic path (19). The VDAC protein reg-
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ulates OMM permeability and is in turn regulated by direct
interactionwith Bcl-2 familymembers aswell as other proteins,
such as hexokinase andmitochondrial creatine kinase (20). Fur-
ther, VDAC is known to be up-regulated in cancer cells (21) and
exhibits elevated binding to hexokinase I and/or hexokinase II.
Due to their higher energy requirements, cancer cells are char-
acterized by a high rate of glycolysis (22, 23). This in turn
requires various genetic and biochemical adaptations, includ-
ing increased expression of mitochondria-bound isoforms of
hexokinase (HK I and HK II) (23–25). Purified HK I has been
shown to interact directly with purified VDAC reconstituted
into a planar lipid bilayer, leading to channel closure. This pre-
vents opening of the permeability transition pore and release of
cytochrome c, thus inhibiting the mitochondrial phase of apo-
ptosis (26). A dynamic equilibrium exists between monomeric
and oligomeric forms of VDAC that determines its interactions
with other proteins and the regulated formation of pores large
enough to allow the release of apoptogenic factors from mito-
chondria (27).
We show here a prosurvival effect of the HEV Orf3 protein
and relate this to its ability to modulate VDAC expression and
oligomerization. We also show that VDAC oligomerization in
Orf3-expressing cells protects against an apoptotic insult and is
accompanied by enhanced hexokinase I expression and its
interaction with VDAC. These findings are discussed in the
context of HEV pathogenesis.
EXPERIMENTAL PROCEDURES
Plasmids, Cell Lines, and Antibodies—The expression vec-
tors for orf3, pSG-ORF3 (8), and pORF3-ECFP (15) have been
described earlier. The orf3 and vector control stable cell lines
(12) as well as polyclonal antibodies to Orf3 (8) have also been
described earlier. The VDAC1, VDAC2, and VDAC3 genes
were generously provided by Dr. Michael Forte (Vollum Insti-
tute for Advanced Biomedical Research, Oregon Health Sci-
ences University, Portland, OR). The VDAC antibody was pur-
chased fromCell Signaling Technology (Beverly,MA), whereas
the Alexa dye-conjugated secondary antibodies were procured
from Molecular Probes, Inc. (Eugene, OR). The EGFP-cyto-
chrome c expression vector was kindly provided by Dr. Israrul
Haq Ansari (University of Nebraska, Lincoln, NE).
Suppressive Subtractive Hybridization—Suppressive sub-
tractive hybridization was performed using orf3 and vector
control stable cell lines according to Mishra et al. (28). Briefly,
total RNA was isolated from the cells and mRNA prepared by
magnetic separation after annealingwith biotinylated oligo(dT)
primer and immobilizing it onto streptavidin-linked paramag-
netic beads. Five g of mRNA from each cell line was used to
synthesize first strand cDNA by separately priming with P1-dT
and P2-dT oligonucleotide primers (28). After reverse tran-
scription, mRNA and excess primers were removed before
ligating the P1–3 and P2–3 adaptor oligonucleotides to the
3-ends of first strand cDNAswithT4RNA ligase (28). The first
strand cDNA population from control samples was PCR-am-
plified using 5 biotinylated P1 forward and nonbiotinylated P1
reverse primers (28). The PCR conditions included 30 cycles of
94 °C for 1 min, 55 °C for 1 min, and 72 °C for 3 min. The bio-
tinylated double-stranded cDNAs thus obtained were immobi-
lized onto streptavidin-linked paramagnetic beads, whereas the
nonbiotinylated complementary antisense strands were dena-
tured with 0.15 M NaOH for 10 min at room temperature and
separated out from the beads with a magnet. The beads were
washed twice with 0.15 M NaOH and used for the first round of
cDNA subtraction. The unamplified first strand cDNAs that
were made from ORF3/4 cells were hybridized for 5 h at 65 °C
with PCR-amplified sense strand cDNAs of control cells that
were immobilized onto the magnetic beads. The hybrids
between the sense strand and the common complementary
antisense cDNA strands, as well as the beads, weremagnetically
separated. Differentially up-regulated genes in ORF3/4 cells
remained in the hybridization solution and were PCR-ampli-
fied in a sequence-independentmannerwith P2 forward andP2
reverse primers. The PCR conditions included 30 cycles of
94 °C for 1 min, 55 °C for 1 min, and 72 °C for 3 min. The PCR-
amplified differentially expressed cDNA population was then
cloned into the pGEMT vector (Promega, Madison, WI). The
recombinant plasmids thus obtained were digested with NotI;
depending on insert size, six different clones were selected and
sequenced, and the genes were identified by BLAST analysis.
Northern Blotting—For probe preparation, theVDAC1 clone
was digested with AccI-BglI to give a 230-bp fragment, the
VDAC2 clonewas digestedwithAccI-HindIII for a 530-bp frag-
ment, and the VDAC3 clone was digested with HindIII for a
470-bp fragment. The probe fragments corresponded to the
3-ends of the VDAC genes and showed very low nucleotide
homology, enabling specific detection of VDAC RNAs by
Northern blotting. Total RNAwas isolatedwithTrizol (Invitro-
gen) as per themanufacturer’s guidelines. Samples of total RNA
(20 g/lane) were denatured in 17.4% (v/v) formaldehyde, 50%
(v/v) formamide, 20 mM 3-(N-morpholino) propanesulfonic
acid, 5 mM sodium acetate, and 1 mM EDTA (pH 7.0) for 5 min
at 65 °C and separated on a 1% (w/v) agarose, 0.66 M formalde-
hyde gel. Following electrophoresis, theRNAwas transferred to
a nylon membrane (HyBond-N; Amersham Biosciences) by
capillary blotting for 24 h in 10 SSC (1 SSC: 150 mM NaCl
and 15 mM sodium citrate, pH 7.0) and UV-cross-linked to the
nylonmembrane. The blot was stained withmethylene blue for
RNA integrity and equivalence by determining transfer of 28
and 18 S rRNA from the gel. Membranes were prehybridized at
42 °C for 5 h in hybridization solution containing 50% (v/v)
deionized formamide, 50 mM sodium phosphate, 0.8 M NaCl,
2% (w/v) SDS, 100g salmon spermDNA/ml, 20g of transfer
RNA/ml, and 1 Denhardt’s solution (50 Denhardt’s solu-
tion: 1% each of bovine serum albumin, Ficoll, and polyvi-
nylpyrrolidone). The VDAC probes were labeled with
[-32P]dCTP using a random priming labeling kit (Hexalabel
DNA labeling kit; Fermentas). Hybridization was carried out at
42 °C for 20 h in hybridization solution containing the radiola-
beled VDAC isoform-specific probe. Membranes were washed
sequentially once in 2 SSC at room temperature for 10 min
and twice with 0.5 SSC, 0.1% SDS at 65 °C for 30 min. The
bands were visualized by autoradiography.
Immunoprecipitation and Western Blotting—Cells were
lysed with a buffer containing 20 mM Tris-HCl, pH 7.5, 150
mM NaCl, 1 mM EDTA, 1 mM EGTA, 1% Triton X-100, and a
protease inhibitor mixture (Roche Applied Science). The cell
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lysates were normalized for protein content, and 1 mg of total
proteins in 500 l of lysis buffer were incubated with 10 l of
Protein G-agarose (Amersham Biosciences) beads for 1 h at
4 °C. The precleared lysate was then incubated with 2 g of
anti-hexokinase I polyclonal antibody (sc-6518; Santa Cruz
Biotechnology, Inc., Santa Cruz, CA) overnight at 4 °C. This
was followed by incubation with 10 l of Protein G-agarose
beads for 2 h at 4 °C.After fivewashings in lysis buffer, the beads
were boiled in Laemmli buffer, and the proteins were separated
by SDS-PAGE. For Western blotting, the separated proteins
were transferred to a nitrocellulose membrane (MDI,
Advanced Microdevices Pvt. Ltd., Ambala, India). After block-
ing with Tris-buffered saline (TBS) containing 5% nonfat milk
(Nestle) for 1–2 h at room temperature, the membrane was
washed with TBST (TBS containing 0.1% Tween 20) and incu-
bated overnight at 4 °Cwith the primary antibody appropriately
diluted in TBST containing 5% bovine serum albumin. The blot
was then washed three times for 10 min each with TBST and
then incubated with horseradish peroxidase-linked anti-rabbit
or anti-goat IgG diluted in TBST containing 5% nonfat milk.
Chemiluminescent detection of proteins was carried out using
the Phototope horseradish peroxidase Western blot detection
system (Cell Signaling Technology, Beverly, MA) according to
the supplier’s protocol. In all Western blotting experiments,
total ERK levels were evaluated as loading controls.
Cell Viability Assay—For the cell survival assay, cells were
treated with 1M staurosporine (STS) for 10 h, followed by two
washes with PBS. The treated cells were then stained with
0.25% Coomassie Brilliant Blue R-250 in 10% acetic acid, 50%
methanol (v/v) andwashed, and the stained colonies of live cells
were counted on an Elispot Reader (Bioreader 4000; Biosys).
The cell viability was also evaluated in attached cells using a
colorimetric assay based on 3-[4,5-dimethylthiazol-2-yl]-2,5-
diphenyltetrazolium bromide (MTT) staining (29) that meas-
ures mitochondrial function (30, 31). The cells were either
mock-treated or treated with various concentrations of STS for
the indicated time(s) followed by the MTT assay. All data are
expressed as percentages with respect to mock-treated cells
and represent the mean  S.E. of at least three independent
experiments.
Mitochondrial Membrane Potential Measurement—The
change in mitochondrial membrane potential (m) was ana-
lyzed by flow cytometry using the m-sensitive dye 5,5,6,6-
tetrachloro-1,13,3-tetraethyl benzimidazolcarbocyanine io-
dide (JC-1; Sigma) (32). Briefly, cells were harvested, washed
once in PBS, and then resuspended in complete culture
medium containing 1M JC-1 at 37 °C for the indicated time(s)
in the presence or absence of 2 M STS. Stained cells were then
washedwith PBS and analyzed by flow cytometry. The emission
maxima of JC-1 monomers and aggregates are 527 nm (FL-1
channel) and 590 nm (FL-2 channel), respectively.
Microscopy—For immunofluorescence staining and colocal-
ization experiments,Huh-7 cells were seeded at about 30% con-
fluence on coverslips in 12-well plates, grown for 18 h, and then
cotransfected with Ds-Red Mito and EGFP-cytc, either with or
without ECFP-ORF3. Also, pCN and ORF3/4 cells were co-
transfected to express Ds-Red Mito and EGFP-cytc. At 48 h
post-transfection, the cells were treated with 2 M STS for 2 h,
washed with PBS, fixed in 4% paraformaldehyde for 15 min at
room temperature, and washed once again in phosphate-buff-
ered saline. The cells were then mounted using Antifade (Bio-
Rad) and sealed with a synthetic rubber-based adhesive, Fevi-
bond (Fevicol; Pidilite Industries). Confocal images were
collected using a 60 planapo objective on a Bio-Rad Radiance
2100 system attached to aNikon invertedmicroscope.Multiple
randomly selected cells from each group were analyzed, and
the amount (percentage) of EGFP-cytochrome c that colocal-
ized with Ds-Red Mito was quantitated with the LaserPix soft-
ware (Bio-Rad). Such colocalization calculations are independ-
ent of the relative intensities in the green and red channels.
Cross-linking Experiments—The pCN andORF3/4 cells were
treated with or without 5 M STS for 30 min followed by a PBS
wash. Cells were lysed by five or six repeated freeze-thaw cycles
in liquid nitrogen and at room temperature. The unclarified
lysate was then incubated with 1 mM DSP (Pierce) dissolved in
Me2SO for 30 min at 30 °C according to manufacturer’s proto-
col. TheMe2SO concentration in control and reagent-contain-
ing samples was up to 2.5% (v/v). The reaction was stopped by
adding 50 mM Tris, pH 7.5, and the samples were analyzed on
nonreducing as well as reducing SDS-PAGE.
siRNA-mediated Knockdown of Orf3 and VDAC—The orf3
siRNA5-UCACGUCGUAGACCUACCAUU-3was designed
using the “Dharmacon siDESIGNCenter” program available on
the World Wide Web and was obtained from Dharmacon
(Lafayette, CO) as a duplex. The VDAC1-specific and GFP
siRNAs were obtained as siGENOME SMARTpool reagent
fromDharmacon. Cells were transfected using RNAiFect (Qia-
gen, Hilden, Germany) with 200 nM VDAC siRNA (si-V), 300
nM orf3 siRNA (si-3), and 200 nMGFP siRNA (si-G). All siRNA-
related experiments were performed in 12-well culture plates,
and GFP-specific siRNA was used as nonspecific control. For
siRNA-based survival experiments, cells were transfected, with
either the orf3 siRNA for 48 h or theVDAC siRNA pool for 36 h
followed by treatment with 2 M STS for 2 h. The cell viability
assays were then performed as described above.
Reverse Transcription-PCR Analysis—Total RNA was iso-
lated from pCN and ORF3/4 cells using the Trizol reagent
(Invitrogen). Four g of RNA in a 25-l reaction mixture was
used for cDNA synthesis with Reverse Transcriptase (Promega,
Madison, WI) according to the supplier’s protocol. Of this, 0.5
l of cDNA was used as a template for PCR amplification of
target genes. The PCRs were performed in a 50-l volume con-
taining 1 reaction buffer, 200 M dNTPs, 10 pmol of each
primer, and 1.25 unit of TaqDNA polymerase (Real Biotech
Corp., Taipei, Taiwan), for 35 cycles of 94 °C for 30 s, 55 °C for
30 s, 72 °C for 30 s, and a final extension at 72 °C for 2 min. The
primer sequences for hexokinase I and II were retrieved from
the World Wide Web and custom-synthesized. Primer pairs
HK1-F (5-TCCTGGCCTATTACTTCACGG-3) and HK1-R
(5-GGACCTTACGAATGTTGGCAA-3) and HK2-F (5-
GAGCCACCACTCACCCTACT-3) andHK2-R (5-ACCCA-
AAGCACACGGAAGTT-3) were used to amplify hexokinase
I and II, respectively. The histone H4 gene was amplified as a
reference control using the primersHISTH4-F (5-TGAGAGAC-
AACATTCAGGGCATCAC-3) and HISTH4-R (5-CGCTTG-
AGCGCGTACACCACATCCAT-3). The amplified products
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were resolved on a 2% agarose gel and visualized following
stainingwith ethidiumbromide. The sizes of the amplified frag-
ments were as follows: hexokinase I, 194 bp; hexokinase II, 130
bp; histone H4, 211 bp.
RESULTS
Suppression subtractive hybridization was performed using
control (pCN) andOrf3-expressing (ORF3/4) stable cell lines as
described under “Experimental Procedures.” The differentially
expressed cDNAs were PCR-amplified and cloned. A number
of clones were randomly picked and analyzed by restriction
digestion. Clones with varying sizes of inserts were identified
and sequenced to determine the identity of the up-regulated
genes they represented. One such up-regulated gene was
VDAC1.
To validate Orf3-mediated increased expression of VDAC,
we carried out Northern and Western blot analyses. The
ORF3/4 cell line showed higher levels ofVDAC1RNA (Fig. 1A).
Using probes from the 3-end of the VDAC gene, where mini-
mal homology was observed betweenVDAC1 and its two other
isoforms,VDAC2 andVDAC3, increased expression of all three
VDAC isoforms was observed in Orf3-expressing cells (Fig.
1A). To confirm that the higher RNA levels were also reflected
in higher levels of the VDAC protein, Western blotting was
performed on lysates prepared from pCN and two independent
Orf3-expressing cell lines, ORF3/1 and ORF3/4. Western blot-
ting using anti-VDAC antibodies showed higher expression of
the VDAC protein in Orf3-expressing cells (Fig. 1B, top, lanes
1–3). Since the anti-VDAC antibodies reacted with all three
isoforms of the protein, it was not possible to study the effects
on individual isoforms. In another experiment, human hepa-
toma Huh-7 cells that were transiently transfected with an orf3
expression vector (pSG-ORF3) also showed higher levels of the
VDAC protein compared with Huh-7 cells transfected with the
empty vector (Fig. 1B, top, lanes 4–6).We checked aHeLa/Tet-
OFF-inducible stable cell line5 to show that compared with
control cells, the Orf3-expressing cells showed higher levels of
the VDAC protein (Fig. 1B, bottom, lanes 1–3). These cells
showed leaky expression of Orf3 even in the presence of tetra-
cycline (lane 2); this was also reflected in VDAC expression in
HeLa/Tet-OFF/ORF3 cells in the presence (lane 2) and absence
of tetracycline (lane 3). Thus, using multiple cell line systems,
either transiently transfected or stably expressing Orf3, we
show that increased VDAC expression correlated with Orf3
expression.
The VDAC protein is the principal mitochondrial channel
protein, and its regulated expression is important for cell sur-
vival. A higher VDAC expression level in cells results in cell
death by apoptosis (33). For insight into VDAC overexpression
in Orf3-stable cell lines, we treated the cells with STS, a potent
apoptogenic stimulus. Apoptosis mediated by STS occurs
through a mitochondrial pathway and leads to loss of mito-
chondrial transmembrane potential. Cells that survived STS-
initiated death were initially scored by staining with Coomassie
Blue and counting. Surprisingly, significantly reduced cell
death was observed in ORF3/4 cells compared with the control
pCN cells (Fig. 2A), which was in contrast to previous reports
where higher VDAC expression levels resulted in enhanced
apoptosis and cell death. Although treatmentwith 1MSTS for
10 h killed about 75% of the pCNcells, about 50% of theORF3/4
cells survived this treatment (Fig. 2A). The cell viability was also
evaluated by using a colorimetric assay based onMTT staining.
The pCN and ORF3/4 cells were treated with various concen-
trations of STS for different times. Although pCN cells showed
greater sensitivity toward STS-mediated death, ORF3/4 cells
resisted this effect. An optimum 2 M STS treatment for 2 h
resulted in 40% cell death in pCN cells, whereas only about
20% death was observed in ORF3/4 cells (Fig. 2B).
Mitochondria are critical integrators of apoptosis, the initia-
tor event being the loss of mitochondrial potential. We there-
fore compared mitochondrial depolarization in control and
Orf3-expressing cells following STS treatment. To detect
changes in the mitochondrial membrane potential, we used
JC-1, a cationic dye that detects mitochondrial depolarization
in apoptotic cells by a shift in its fluorescence emission. Treat-
ment with STS and JC-1 stainingwas followed by flow cytomet-
ric analysis of the cells. Although the pCN cells showed a quan-
titative loss of mitochondrial potential characterized by a large
increase in fluorescence (Fig. 3A), only minimal shifts were
observed in ORF3/4 cells (Fig. 3B).
The retention of mitochondrial potential in Orf3-expressing
cells in response to STS suggested the involvement of other
players in controlling mitochondrial membrane integrity. The
mitochondrial VDAC acts as a docking site for various pro- and
antiapoptotic proteins that affect its oligomerization status.
Monomeric VDAC is reported to form the functional channel
whose conductance decreases following VDAC oligomeriza-
tion (27). To evaluate the oligomeric status of VDAC in Orf3-
expressing cells, we used the thiol-cleavable bifunctional chem-
ical cross-linker DSP. Chemical cross-linking of lysates from
5 M. Rajala and S. Jameel, unpublished observations.
FIGURE 1. Analysis of VDAC expression in cell lines. A, total RNA extracted
from pCN () and ORF3/4 () cells was Northern blotted with orf3-, VDAC1-,
VDAC2-, and VDAC3-specific probes. The 18 and 28 S rRNA stainedwithmeth-
ylene blue served as a control for equal loading and RNA integrity. B, Western
blot analysis for VDAC expression was carried out on lysates prepared from
various cell lines. These included the following: pCN (lane 1), ORF3/1 (lane 2),
ORF3/4 (lane 3), vector-transfected Huh-7 cells (lane 4), and pSG-orf3-trans-
fected Huh-7 cells (lanes 5 and 6). Western blotting of cell lysates with anti-
Orf3 and anti-ERK antibodies served as expression and loading controls,
respectively. The bottom panel shows results fromHeLa/Tet-OFF cells (lane 1)
or HeLa/Tet-OFF-ORF3 cells in the presence (lane 2) or absence (lane 3) of
tetracycline. A nonspecific band detected with anti-VDAC antibodies served
as a loading control; Western blotting for Orf3 showed its expression in these
cells.
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pCN and ORF3/4 cells with this membrane-permeable cross-
linker was performed following STS treatment. The lysates
from cross-linked pCN and ORF3/4 cells were separated by
SDS-PAGE under nonreducing and
reducing conditions followed by
Western blotting with anti-VDAC
antibodies. Substantially higher
levels of VDAC oligomers were
observed in ORF3/4 cells compared
with pCN cells (Fig. 4, lanes 1–8).
These oligomers were formed spe-
cifically by cross-linking VDAC
monomers as evidenced by their
disappearance following thiol-me-
diated cleavage of the DSP spacer
arm (Fig. 4, lanes 9–12).
Hexokinase (HK), the first en-
zyme in the glycolytic pathway, is
reported to bind to the mitochon-
drial membrane due to its interac-
tion with VDAC. This interaction is
important for the integration of gly-
colysis with mitochondrial energy
metabolism and the antiapoptotic
role of HK in cells (34). Hexokinase
binding cross-links VDAC and sup-
presses the release of intermem-
brane space proteins, thus prevent-
ing apoptosis (35). To evaluate the
status of HK in Orf3-expressing
cells, we carried out reverse tran-
scription-PCR analysis of RNA pre-
pared from pCN and ORF3/4 cells.
Although there was a large increase
in HK I expression in ORF3/4 cells,
there was no change in the expres-
sion ofHK II in these cells compared
with the pCN cells (Fig. 5A). The
Western blot analysis of these cell
lines using antibodies specific for
HK I and HK II also revealed higher
levels of HK I in Orf3-expressing
cells, whereas the HK II levels
remained unchanged (Fig. 5B).
Human hepatoma Huh-7 cells tran-
siently transfected with pSG-ORF3
also exhibited higher levels of HK I
(Fig. 5C). A direct interaction
betweenHK I andVDACwas tested
by immunoprecipitation of cell
lysates with anti-HK I antibodies
followed by Western blotting with
anti-VDAC antibodies. Anti-HK I
antibodies co-immunoprecipitated
VDAC from pCN and ORF3/4 cells.
However, a larger amount of the
VDACproteinwas immunoprecipi-
tated from Orf3-expressing cells
compared with control cells (Fig. 5D).
If Orf3 conferred resistance against a strong apoptotic stim-
ulus (STS) and if it was indeed mediated through the up-regu-
FIGURE 2. TheOrf3 protein protects cells from staurosporine-induced death. A, control (pCN) and ORF3/4
cells were treated with 1 M STS for 10 h followed by staining with Coomassie Brilliant Blue R-250 and quanti-
tation of surviving cells as described under “Experimental Procedures.” The picture on the left is representative
of a survival assay in a 12-well plate. The bar graph on the right shows results from three independent experi-
ments. The dark and light bars show results for pCN and ORF3/4 cells, respectively. B, cell viability was also
evaluated by using a colorimetric assay based on theMTT uptake. The pCN andORF3/4 cells were treatedwith
various concentrations of STS for 30min, 60min, 1 h, and 5 h, followed by theMTT assay. Data are expressed as
percentage of cell viability with respect to control and represent an average of three independent
experiments.
FIGURE 3. The Orf3 protein prevents mitochondrial depolarization. The pCN (A) and ORF3/4 (B) cells were
either mock-treated or treated with 2 M STS for 30 min, 1 h, and 2 h followed by JC-1 staining as described
under “Experimental Procedures.” The JC-1-stained cells were then subjected to flow cytometry, and results
were analyzed for the FL-1 channel that scores JC-1 monomers. The solid and dotted lines show JC-1 staining
without or with STS treatment, respectively.
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lation of VDAC and HK I and their enhanced interaction, an
siRNA-mediated knockdown of Orf3 should affect this survival
advantage. To confirm the protective effects of Orf3, we trans-
fected ORF3/4 cells with an orf3-specific siRNA and 48 h later
treated the transfected cells with 2 M STS for 2 h, followed by
MTT staining. Although a majority of GFP siRNA-transfected
ORF3/4 cells survived the STS treatment, this number was
reduced in the orf3 siRNA-transfected cells (Fig. 6A). Although
this reduction was not dramatic, it was reproducible. This pool
is likely to contain a mixture of cells that received the orf3
siRNA following transfection and those that did not, thus
potentially reducing the overall siRNA effect. The siRNA
against orf3 also led to a decrease in HK I and VDAC levels (Fig.
6B). To demonstrate a direct role for VDAC in protection from
cell death, we transfected pCN or ORF3/4 cells with an siRNA
pool directed against VDAC. This reduced endogenous VDAC
protein levels by about 80–90% in both cell lines at 36 h post-
transfection (Fig. 6C). At this time, cells were treated with STS,
and cell viability was scored by the MTT assay. Reduced cell
survival was found inVDAC siRNA-transfected pCNcells com-
pared with mock-transfected cells following STS treatment
(Fig. 6D). Similarly, ORF3/4 cells also showed reduced survival
following siRNA-mediated VDAC knockdown (Fig. 6D); the
effects were, however, not as pronounced as those observed for
pCN cells.
The release of cytochrome c from mitochondria is the first
irreversible step toward the commitment of cells to apoptosis.
We therefore assessed the release of cytochrome c from mito-
chondria. Control andORF3/4 cells were transfected to express
EGFP-cytc together with amitochondrial marker, DsRed-mito.
Huh-7 cells were also transiently transfected with EGFP-cyto-
chrome c and DsRed-mito in the absence or presence of ECFP-
tagged ORF3. After 48 h, the cells were treated with 2 M STS
for 2 h and analyzed by confocalmicroscopy. Control (pCN and
Huh-7) cells showed extensive mitochondrial disintegration
and release of cytochrome c in the cytosol following STS treat-
ment (Fig. 7A). In mock-treated cells, EGFP-cytc was found to
quantitatively localize to the mitochondria (not shown). How-
ever, in ORF3/4 cells and ECFP-ORF3-expressing Huh-7 cells,
EGFP-cytochrome c was clearly retained in the mitochondria
following STS treatment, as evidenced by its colocalizationwith
the DsRed-mito marker (Fig. 7A). The degree of extramito-
chondrial EGFP-cytc was determined using the LaserPix colo-
calizationmodule and plotted in Fig. 7B. Although control cells
(pCN and Huh-7) showed about 75–80% of cytc to be released
from mitochondria, only about 20–25% of it was released in
Orf3-expressing cells. In the same cells, the Orf3 protein was
found not to localize to the mitochondria; thus, the protective
effect was not due to a direct association of Orf3 with the mito-
chondria. Together, the JC-1 and cytc results showed the Orf3
prosurvival effect to be due to its ability to preserve mitochon-
drial integrity in the face of an apoptotic insult.
DISCUSSION
The Orf3 protein appears to modulate the host cell environ-
ment for efficient replication and propagation ofHEV.Wehave
shown earlier that this viral protein up-regulates ERK activity
(12) and that this is due to its ability to bind and inhibit mito-
gen-activated protein kinase phosphatases that negatively reg-
ulate ERK activation (15). The Orf3 protein also binds -1-
microglobulin, a protein with immunosuppressive properties,
and promotes its secretion into the extracellular medium (36).
Although not directly demonstrated, this is likely to have an
impact on the host immune response, at least in themilieu of an
infected liver. The prolonged activation of ERK would have a
prosurvival effect, protecting the infected cell from premature
FIGURE 4. VDAC oligomerization status. Control and ORF3/4 cells were
either mock-treated or treated with 5 M STS for 30 min. The cells were then
lysed by freeze-thaw, and the unclarified lysates were treated with themem-
brane-permeable bifunctional cross-linker DSP at a concentration of 1mM. As
a control, cells were treatedwith an equivalent volume ofMe2SO. The lysates
were then mixed with Laemmli SDS dye loading buffer (-mercaptoethanol-
free for nonreducing conditions), boiled, and resolved on nonreducing (lanes
1–8) as well as reducing (lanes 9–12) SDS-polyacrylamide gels. Western blot-
ting was performed using anti-VDAC antibodies. The arrows indicate oligo-
meric forms of VDAC.
FIGURE 5.Hexokinase expression and its interactionwithVDAC.A, reverse
transcription-PCR analysis was carried out to estimate the expression of his-
tone H4 (reference control), hexokinase I (HK I) and hexokinase II (HK II) genes
in pCN (lanes 1, 3, and 5) andORF3/4 (lanes 2, 4, and 6) cells. Themolecular size
markers are shown. B, Western blot analysis of control and ORF3/4 cells was
performed using anti-HK I or HK II antibodies. Western blotting for ORF3 and
ERK served as expression and loading controls. C, lysates prepared from
Huh-7 cells transiently transfectedwith either control vector orpSG-orf3were
subjected to Western analysis using anti-HK I antibody. Levels of total ERK
served as loading control. D, the lysates prepared from control and ORF3/4
cells were immunoprecipitated with anti-HK I antibodies followed by West-
ern blotting with anti-VDAC antibodies.
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cell death and increasing the efficiency of viral replication.
Thus, Orf3 appears to be a regulatory protein that is likely to
influence multiple pathways that promote establishment and
propagation of HEV infection. Indeed, Orf3 was shown to be
required for viral infection following intrahepatic inoculation
of HEV genomic RNA directly into
monkey liver (37) but was found to
be dispensable when HEV genomic
RNA was tested by transfection of
cells in vitro (38, 39). Since no effi-
cient cell culture system, small ani-
malmodels, or in vitro genomic rep-
licon systems are available for
studying HEV biology, our strategy
is based on subgenomic expression
to study the characteristics and pos-
sible functions of the Orf3 protein.
We used suppression-subtractive
hybridization (28), a PCR-based
technique for cloning differentially
expressed genes, to search for cellu-
lar genes whose expression was
increased in Orf3-expressing cells.
For this, we used a cell line that sta-
bly and constitutively expressed
Orf3; another cell line made with
the empty expression vector served
as a control. At least six different
up-regulated genes were cloned
and sequenced. One of these
matched the gene for VDAC, and
this was verified by Northern blot-
ting. The RNAs for all three iso-
forms of VDAC were found to be
up-regulated in Orf3-expressing
cells. Increased levels of the VDAC
protein in these cells were con-
firmed using multiple cell lines
that included transient as well as
stable expression of Orf3. Further,
siRNA-mediated silencing of Orf3
expression led to reduced VDAC
expression, supporting a direct
causal relationship between these
proteins.
Mitochondria are organelles that
coordinate cellular energy metabo-
lism and integrate signals for cell
survival and apoptosis (35, 40).
Exchange of metabolites across the
inner and outer mitochondrial
membranes and themaintenance of
a transmembrane potential are crit-
ical for normal cell physiology. The
VDAC is an important mitochon-
drial protein whose expression lev-
els are regulated and critical for cell
survival. An imbalance in VDAC
expression disturbs cellular metabolism, with lower levels
resulting in slow growth and up-regulation, leading to apopto-
sis. A preliminary analysis was performed by scoring cell viabil-
ity of Orf3-expressing cells in response to STS, a potent apo-
ptotic agent that acts at the level ofmitochondria. Interestingly,
FIGURE 6. Orf3-, VDAC-, and STS-mediated cell death. A, the ORF3/4 cells were transfected with either
control siRNA forGFP (si-G) or directed against orf3 (si-3), and 48 h later, the cells were treatedwith 2M STS for
2 h. Cell viability was then measured by the MTT assay. Controls included mock transfection and no STS
treatment. The values shown are means S.E. of three independent experiments. B, the lysates from mock-,
control (si-G)-, ororf3 siRNA (si-3)-transfectedORF3/4 cellswereWesternblottedwithHK I, VDAC,Orf3, and ERK
antibodies. C, Western blot analysis of lysates frommock-, control (si-G)-, or VDAC (si-V) siRNA-transfected cells
36 h post-transfection to estimate levels of VDAC and ERK (loading control) proteins. D, pCN (dark bars) and
ORF3/4 (light bars) cells were eithermock-transfected or transfectedwithGFP siRNA (si-G) or VDAC siRNA (si-V).
After 36 h, these cells were treatedwith 2M STS for 2 h and then assayed for cell viability by theMTTmethod.
Mock-treated cells were taken as 100% survival. The results are presented asmean S.E. of three independent
experiments.
FIGURE 7. Effect of Orf3 on mitochondrial cytochrome c release. A, control (pCN) and ORF3/4 cells were
cotransfected with pDs-Red-Mito and EGFP-cytc. Huh-7 cells were cotransfected to express Ds-Red Mito and
EGFP-cytochrome ceitherwithout orwithplasmid ECFP-orf3. After 48h, the cellswere treatedwith 2MSTS for
2 h, fixed, and visualized by confocal microscopy. The individual images and theirmerged pictures are shown.
B, the amount of cytochrome c released from themitochondria to the cytoplasm in these cells was determined
by LaserPix software and plotted. Average cytochrome c release values derived from at least six randomly
selected cells are shown.
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Orf3-expressing cells showed better survival to STS-mediated
death when assayed by two different methods, although higher
VDAC expression levels are correlated with increased apopto-
sis. Since STS is known to cause mitochondrial depolarization,
the mitochondrial membrane potential ()-sensitive dye
JC-1 was used to assess this as well. This dye accumulates as
aggregates in the mitochondria, resulting in red fluorescence,
the brightness of which is proportional to and varies among
different cell types. However, in apoptotic and necrotic cells,
JC-1 exists in its monomeric form in the cytoplasm and stains
cells green. Although the control cells showed quantitative
mitochondrial depolarization following STS treatment, the
ORF3/4 cells were again better protected. Increased VDAC
expression on one hand and cell survival and mitochondrial
depolarization results on the other suggested the involvement
of other interacting partners and compensatorymechanisms in
the fate of Orf3-expressing cells.
There are two main models to explain the release of apopto-
genic factors from mitochondria. One is based on increased
Ca2 uptake, swelling of thematrix, andmitochondrial rupture
(41–44). The other model supports formation of a pore in the
OMMthat allows passage of largemoleculeswithout damage to
the organelle (43, 45–48). Recent reports suggest that VDAC
forms this pore whose opening is regulated by association with
proteins of the Bcl-2 family as well as other proteins like hex-
okinase and mitochondrial creatine kinase. Microinjected
VDAC-specific antibodies inhibit apoptosis induced by micro-
injected Bax, demonstrating the importance of VDAC cross-
linking in cells (48).
To understand the mechanism(s) underlying the mainte-
nance of mitochondrial potential in ORF3/4 cells, we assessed
the oligomeric nature of VDAC in these cells through chemical
cross-linking studies. The membrane-permeable but thiol-
cleavable cross-linker, DSP, showed the presence of oligomeric
VDAC in ORF3/4 cells when the lysates were analyzed under
nonreducing conditions but not under reducing conditions. It
is known thatmonomeric VDAC serves as the functional chan-
nel, and a relatively intimate contact exists betweenmonomers
in the VDAC, whereas cross-linked VDAC results in decreased
channel conductance and voltage-independent channel activity
(27). It has been shown that cross-linking ofVDACprevents the
movement of cytochrome c from themitochondria to the cyto-
plasm (27). A dynamic equilibrium exists between monomeric
and oligomeric VDAC that upon cross-linking shifts in favor of
the latter. Oligomeric VDAC is also a binding site for the hex-
okinase I tetramer (26, 49), this binding leading to closure of the
VDAC pore, preventing the release of proapoptotic molecules.
Our hexokinase experiments further strengthened the corre-
lation between up-regulated VDAC and increased cell survival.
Although HK I and HK II are functionally similar, they differ in
their tissue distribution (30). Hexokinase binding to VDAC
suppresses the release of intermembrane space proteins and
inhibits apoptosis, thereby contributing to the survival advan-
tage of cells (31, 50). This is achieved by the binding of tet-
rameric HK to VDAC tetramers (26, 51–53). Both isoforms
interact through a hydrophobic 15-amino acid sequence in
their N-terminal region with mitochondrial VDAC (51, 54). In
ORF3/4 cells, we observed higher expression levels of HK I, the
isoform predominantly present in hepatocytes; there was no
effect on the levels of HK II, an isoform known to be weakly
expressed in liver cells (50, 55). Transient expression of Orf3 in
Huh-7 cells also had a similar effect on HK I levels. In an inde-
pendent microarray analysis, VDAC and HK I, but not HK II,
genes were found to be up-regulated in ORF3/4 cells compared
with pCN cells (not shown). Co-immunoprecipitation of HK I
and VDAC showed a direct interaction between these proteins.
Further, higher amounts of VDACwere pulled downwith HK I
in Orf3-expressing cells compared with pCN cells. This inter-
action between HK I and VDAC would prevent opening of the
pore and release of the proapoptotic protein cytochrome c,
thereby suppressing the initiation of apoptosis.
The VDAC channel controls the release of solutes, including
cytochrome c and other proapoptotic molecules residing in the
intermembrane space ofmitochondria.We tested this inHuh-7
cells transiently transfected with EGFP-cytc, either alone or
together with ECFP-ORF3. Following STS treatment, large
amounts of EGFP-cytc were released from the mitochondria;
this effect wasmissing inHuh-7 cells that also expressed ECFP-
ORF3. Similar results were obtainedwith cells stably expressing
Orf3. Reducing VDAC expression through transfection of its
specific siRNA made cells more susceptible to STS; this effect
wasmore pronounced in control compared with Orf3-express-
ing cells. A similar effect was also observed when orf3 siRNA
was used. In that case, although the effects on Orf3 or VDAC
expression were not dramatic, this down-regulation still made
orf3 siRNA-transfected cells more prone to STS-mediated
death as seen in the cell viability assay. Together, these results
provided an explanation for Orf3-mediated protection of cells
fromSTS-inducedmitochondrial depolarization, cytochrome c
release, and death. In related work, we have also observed that
Orf3 protects cells from death induced by U0126 and
LY294002, which are pharmacological inhibitors of the ERK
and phosphatidylinositol 3-kinase/Akt signaling pathways.6
A number of viral proteins target mitochondria for the sup-
pression or induction of apoptosis (55, 57). Importantly, it
appears that such viral proteins have little or no structural sim-
ilarity and that they target very different mitochondrial recep-
tors (58). Of the mitochondrial proteins that interact with viral
proteins, several are also involved in the physiological regula-
tion of mitochondrial membrane potential in response to
endogenous regulators of apoptosis, such as the Bcl-2 family
proteins, ANT, VDAC, and PBR (59).Many viruses also encode
death-inhibitory Bcl-2 analogs that preferentially localize to
mitochondria and may interact with the proapoptotic Bax pro-
tein. Examples of this include the Epstein-Barr virus BORFB2F
and BALF1 proteins, the African swine fever virus 5-HL/A179L
protein, the herpesvirus saimiri HVS-Bcl-2 protein, the Kaposi
sarcoma-associated herpesvirus 8 KSBcl-2 protein, the bovine
herpesvirus 4 BHRF-1 protein, and the murine herpesvi-
rus-68 M11 protein (55). The hepatitis B virus X protein
shares 31% homology with human VDAC3 and colocalizes
with it to the mitochondria (60). Thus, it appears that viruses
exploit several distinct apoptosis-regulatory pathways at the
level of mitochondria.
6 R. Arya and S. Jameel, unpublished observations.
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Based on the current study, we propose that theOrf3 protein
of HEV protects cells from mitochondrial depolarization and
death following apoptotic insult. This is achieved by overex-
pression of the mitochondrial VDAC, a key channel protein
that integrates cellular energy metabolism with the mitochon-
drial phase of apoptosis (61). Although this up-regulation
would lead to enhanced mitochondrial energy metabolism, it
would also make cells susceptible to apoptosis. Up-regulation
of another glycolytic protein hexokinase by Orf3 negates the
proapoptotic function of VDAC. By directly interacting with
and cross-linking VDAC, hexokinase would serve in stabilizing
the mitochondrial permeability transition pore in its closed
state and prevent mitochondrial depolarization, thereby main-
taining mitochondrial membrane integrity and preventing the
subsequent release of cytochrome c into the cytoplasm. Hex-
okinase is also known to compete with the proapoptotic Bax
protein in binding tomitochondria; this would further suppress
Bax-induced cytochrome c release and promote cell survival
(50, 56). Further, being the first enzyme in glycolysis, higher
levels of hexokinase could be an adaptation to maintain effi-
cient ATP transfer for glucosemetabolism to fuel the increased
energy demands of virus-infected cells.
In this work, we have demonstrated a relationship between
expression of the HEVOrf3 protein and the ability of the cell to
cope with apoptotic stress. Results from intrahepatic inocula-
tion of a genomic HEV RNA in monkeys showed orf3 to be
important for infection and disease progression (37). Similar
experiments involving cells in culture show orf3 to be dispen-
sable for the viral life cycle (38). These observations indicate
that Orf3 could be a viral accessory protein. A number of
viruses are known to encode such proteins to optimize the host
cell environment for efficient viral replication (62). For exam-
ple, HIV-1 encodes at least four accessory proteins that are
dispensable for viral replication in cell culture models (63, 64)
but are required for establishment of infection, high titer viral
replication, and AIDS progression in the host (65).
In the present study, we have delineated a biochemical path-
way throughwhich an acute, noncytopathic virus, such asHEV,
can protect infected cells from apoptotic death. This is the first
report that correlates prosurvival effects of a viral protein to
enhanced VDAC and hexokinase expression. An intracellular
survival signal thus would shift the balance toward viral repli-
cation and gene expression, and this would contribute to
pathogenesis.
Acknowledgments—We thank Dr. Michael Forte for the VDAC genes,
Dr. Israrul Haq Ansari for the EGFP-cytochrome c plasmid, Rahul
Arya for the reverse transcription-PCR analysis, Maitreyi Rajala for
the ORF3-HeLa-Tet/OFF cells, Ravinder Kumar for overall cell cul-
ture support, and Anindita Kar-Roy for helpful discussions.
REFERENCES
1. Purcell, R. H., and Ticehurst, J. R. (1988) in Viral Hepatitis and Liver
Disease (Zuckerman, A. J., ed) pp. 131–137, Alan R. Liss, New York
2. Ramalingaswami, V., and Purcell, R. H. (1988) Lancet 1, 571–573
3. Krawczynski, K. (1993) Hepatology 17, 932–941
4. Khuroo,M. S., Teli,M. R., Skidmore, S., Sofi,M.A., andKhuroo,M. (1981)
Am. J. Med. 70, 252–255
5. Nayak,N.C., Panda, S. K., Datta, R., Zuckerman,A. J., Guha,D. K.,Madan-
agopalan, N., and Buckshee, K. (1989) J. Gastroenterol. Hepatol. 4,
345–352
6. Emerson, S. U., Anderson, D., Arankalle, A., Meng, X. J., Purdy, M.,
Schlauder, G. G., and Tsarev, S. A. (2004) in Virus Taxonomy, VIIIth
Report of the ICTV (Fauquet C.M.,Mayo,M.A.,Maniloff, J., Desselberger,
U., and Ball, L. A., eds) pp. 851–855, Elsevier/Academic Press, London
7. Tam,A.W., Smith,M.M.,Guerra,M. E., Huang, C. C., Bradley, D.W., Fry,
K. E., and Reyes, G. R. (1991) Virology 185, 120–131
8. Jameel, S., Zafrullah, M., Ozdener, M. H., and Panda, S. K. (1996) J. Virol.
70, 207–216
9. Zafrullah, M., Ozdener, M. H., Panda, S. K., and Jameel, S. (1997) J. Virol.
71, 9045–9053
10. Zafrullah, M., Ozdener, M. H., Kumar, R., Panda, S. K., and Jameel, S.
(1999) J. Virol. 73, 4074–4082
11. Graff, J., Torian, U., Nguyen, H., and Emerson, S. U. (2006) J. Virol. 80,
5919–5926
12. Korkaya, H., Jameel, S., Gupta, D., Tyagi, S., Kumar, R., Zafrullah, M.,
Mazumdar, M., Lal, S. K., Xiaofang, L., Sehgal, D., Das, S. R., and Sahal, D.
(2001) J. Biol. Chem. 276, 42389–42400
13. Pawson, T. (1995) Nature 373, 573–580
14. Cohen, G. B., Ren, R., and Baltimore, D. (1995) Cell 80, 237–248
15. Kar-Roy, A., Korkaya, H., Oberoi, R., Lal, S. K., and Jameel, S. (2004) J. Biol.
Chem. 279, 28345–28357
16. Colombini, M. (1989) J. Membr. Biol. 111, 103–111
17. Bernardi, P. (1999) Physiol. Rev. 79, 1127–1155
18. Halestrap, A. P., Doran, E., Gillespie, J. P., andO’Toole, A. (2000)Biochem.
Soc. Trans. 28, 170–177
19. Liu, X., Kim, C. N., Yang, J., Jemmerson, R., and Wang, X. (1996) Cell 86,
147–157
20. Tsujimoto, Y., and Shimizu, S. (2002) Biochimie (Paris) 84, 187–193
21. Shinohara, Y., Ishida, T., Hino, M., Yamazaki, N., Baba, Y., and Terada, H.
(2000) Eur. J. Biochem. 267, 6067–6073
22. Arora, K. K., and Pedersen, P. L. (1988) J. Biol. Chem. 263, 17422–17428
23. Pedersen, P. L., Mathupala, S., Rempel, A., Geschwind, J. F., and Ko, Y. H.
(2002) Biochim. Biophys. Acta 1555, 14–20
24. Rempel, A., Bannasch, P., and Mayer, D. (1994) Biochim. Biophys. Acta
1219, 660–668
25. Sebastian, S., and Kenkare, U.W. (1997) Biochem. Biophys. Res. Commun.
235, 389–393
26. Azoulay-Zohar, H., Israelson, A., Abu-Hamad, S., and Shoshan-Barmatz,
V. (2004) Biochem. J. 377, 347–355
27. Zalk, R., Israelson, A., Garty, E. S., Azoulay-Zohar, H., and Shoshan-
Barmatz, V. (2005) Biochem. J. 386, 73–83
28. Mishra, R. N., Ramesha, A., Kaul, T., Nair, S., Sopory, S. K., and Reddy,
M. K. (2005) Anal. Biochem. 345, 149–157
29. Mosmann, T. (1983) J. Immunol. Methods 65, 55–63
30. Carmichael, J., DeGraff, W. G., Gazdar, A. F., Minna, J. D., and Mitchell,
J. B. (1987) Cancer Res. 47, 936–942
31. Vistica, D. T., Skehan, P., Scudiero, D., Monks, A., Pittman, A., and Boyd,
M. R. (1991) Cancer Res. 51, 2515–2520
32. Cossarizza, A., Baccarani-Contri,M., Kalashnikova, G., and Franceschi, C.
(1993) Biochem. Biophys. Res. Commun. 197, 40–45
33. Abu-Hamad, S., Sivan, S., and Shoshan-Barmatz, V. (2006) Proc. Natl.
Acad. Sci. U. S. A. 103, 5787–5792
34. Wilson, J. E. (1995) Rev. Physiol. Biochem. Pharmacol. 126, 65–198
35. Pastorino, J. G., and Hoek, J. B. (2003) Curr. Med. Chem. 10, 1535–1551
36. Tyagi, S., Surjit,M., Roy,A. K., Jameel, S., and Lal, S. K. (2004) J. Biol. Chem.
279, 29308–29319
37. Graff, J., Nguyen, H., Yu, C., Elkins,W. R., St Claire, M., Purcell, R. H., and
Emerson, S. U. (2005) J. Virol. 79, 6680–6689
38. Emerson, S. U., Nguyen, H., Torian, U., and Purcell, R. H. (2006) J. Virol.
80, 10457–10464
39. Huang, Y.W., Opriessnig, T., Halbur, P. G., andMeng, X. J. (2007) J. Virol.
81, 3018–3026
40. Brown, G. C. (2003) Science 299, 838–839
41. Skulachev, V. P. (1996) FEBS Lett. 397, 7–10
42. Vander Heiden, M. G., Chandel, N. S., Williamson, E. K., Schumacker,
HEVOrf3 Protein and VDACOligomerization by Hexokinase
21132 JOURNAL OF BIOLOGICAL CHEMISTRY VOLUME 282•NUMBER 29•JULY 20, 2007
 by guest, on O
ctober 21, 2010
w
w
w
.jbc.org
D
ow
nloaded from
 
P. T., and Thompson, C. B. (1997) Cell 91, 627–637
43. Martinou, J. C., Desagher, S., and Antonsson, B. (2000) Nat. Cell Biol. 2,
E41–E43
44. Doran, E., and Halestrap, A. P. (2000) Biochem. J. 348, 343–350
45. Schlesinger, P. H., Gross, A., Yin, X. M., Yamamoto, K., Saito, M., Waks-
man, G., and Korsmeyer, S. J. (1997) Proc. Natl. Acad. Sci. U. S. A. 94,
11357–11362
46. Antonsson, B., Conti, F., Ciavatta, A., Montessuit, S., Lewis, S., Martinou,
I., Bernasconi, L., Bernard, A., Mermod, J. J., Mazzei, G., Maundrell, K.,
Gambale, F., Sadoul, R., and Martinou, J. C. (1997) Science 277, 370–372
47. Zoratti, M., and Szabo, I. (1995) Biochim. Biophys. Acta 1241, 139–176
48. Ferri, K. F., Jacotot, E., Blanco, J., Este, J. A., Zamzami, N., Susin, S. A., Xie,
Z., Brothers,G., Reed, J. C., Penninger, J.M., andKroemer,G. (2000) J. Exp.
Med. 192, 1081–1092
49. Aflalo, C., and Azoulay, H. (1998) J. Bioenerg. Biomembr. 30, 245–255
50. Pastorino, J. G., Shulga, N., and Hoek, J. B. (2002) J. Biol. Chem. 277,
7610–7618
51. Xie, G. C., andWilson, J. E. (1988) Arch. Biochem. Biophys. 267, 803–810
52. Xie, G., and Wilson, J. E. (1990) Arch. Biochem. Biophys. 276, 285–293
53. Azoulay-Zohar, H., and Aflalo, C. (2000) Eur. J. Biochem. 267, 2973–2980
54. Beutner, G., Ruck, A., Riede, B., and Brdiczka, D. (1998) Biochim. Biophys.
Acta 1368, 7–18
55. Boya, P., Roques, B., and Kroemer, G. (2001) EMBO J. 20, 4325–4331
56. Bryson, J.M., Coy, P. E., Gottlob, K., Hay,N., andRobey, R. B. (2002) J. Biol.
Chem. 277, 11392–11400
57. Tschopp, J., Thome, M., Hofmann, K., and Meinl, E. (1998) Curr. Opin.
Genet. Dev. 8, 82–87
58. Boya, P., Roumier, T., Andreau, K., Gonzalez-Polo, R. A., Zamzami, N.,
Castedo, M., and Kroemer, G. (2003) Biochem. Biophys. Res. Commun.
304, 575–581
59. Boya, P., Pauleau, A. L., Poncet, D., Gonzalez-Polo, R. A., Zamzami, N.,
and Kroemer, G. (2004) Biochim. Biophys. Acta 1659, 178–189
60. Rahmani, Z., Huh, K. W., Lasher, R., and Siddiqui, A. (2000) J. Virol. 74,
2840–2846
61. Downward, J. (2003) Nature 424, 896–897
62. Agrawal, N., Korkaya, H., and Jameel, S. (2000) Curr. Sci. 79, 711–724
63. Steffens, C. M., and Hope, T. J. (2001) AIDS 15, Suppl. 5, 21–26
64. Bour, S., and Strebel, K. (2000) Adv. Pharmacol. 48, 75–120
65. Rucker, E., Grivel, J. C., Munch, J., Kirchhoff, F., and Margolis, L. (2004)
J. Virol. 78, 12689–12693
HEVOrf3 Protein and VDACOligomerization by Hexokinase
JULY 20, 2007•VOLUME 282•NUMBER 29 JOURNAL OF BIOLOGICAL CHEMISTRY 21133
 by guest, on O
ctober 21, 2010
w
w
w
.jbc.org
D
ow
nloaded from
 
